Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-265-8 | CAS number: 10102-05-3
Endpoint summary
Administrative data
Description of key information
No
relevant repeated dose toxicity data were identified for palladium
dinitrate. However, good support for the conclusion that a repeated dose
toxicity study can be waived comes from two sources. Firstly, a
consideration of the known toxicity and physico-chemical properties of
this compound. Palladium dinitrate is a strong acid (pH<2.0) and
exhibits skin corrosivity in vitro. Secondly, there are good-quality
endpoint-specific data on another palladium (II) species. In a combined
repeated-dose and reproductive/developmental toxicity screening test, no
adverse effects were observed at daily doses of palladium(II)
dihydroxide up to 1000 mg/kg bw/day. This supports the hypothesis that,
even if testing were possible, palladium dinitrate would not be expected
to cause any significant systemic toxicity.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No relevant human data were identified. However, consideration of the known toxicity and physico-chemical properties of this compound, as well as endpoint-specific data on another palladium (II) species, provides good support for the conclusion that a repeated dose toxicity study can be waived.
As palladium dinitrate is a strong acid and exhibits skin corrosivity in vitro, repeated dose testing by the oral route is not considered scientifically justified.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
